Who needs to take Fruquintinib?

Fruquintinib (Fruquintinib) is an oral, small molecule angiogenesis inhibitor mainly used to treat patients with advanced colorectal cancer. Aiute is the brand name under which it is sold in China. According to the results of multiple clinical studies, fruquintinib single agent is suitable for patients with metastatic colorectal cancer (mCRC) who have previously received fluorouracil, oxaliplatin and irinotecan-based chemotherapy, as well as patients who have previously received or are not suitable for anti-vascular endothelial growth factor (VEGF) therapy and anti-epidermal growth factor receptor (EGFR) therapy. Therefore, patients who need to take fruquintinib are mainly those with advanced colorectal cancer whose disease has not been controlled or has progressed after other treatments, and who meet the indications for fruquintinib.